Share Name Share Symbol Market Type Share ISIN Share Description
Optibiotix H. LSE:OPTI London Ordinary Share GB00BP0RTP38 ORD 2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.25p -0.36% 68.50p 67.00p 70.00p 69.00p 68.50p 68.75p 54,181 15:58:27
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.0 -1.4 1.8 39.1 53.53

Optibiotix H. (OPTI) Latest News

More Optibiotix H. News
Optibiotix H. Takeover Rumours

Optibiotix H. (OPTI) Share Charts

1 Year Optibiotix H. Chart

1 Year Optibiotix H. Chart

1 Month Optibiotix H. Chart

1 Month Optibiotix H. Chart

Intraday Optibiotix H. Chart

Intraday Optibiotix H. Chart

Optibiotix H. (OPTI) Discussions and Chat

Optibiotix H. Forums and Chat

Date Time Title Posts
21/10/201623:38OptiBiotix - The uncensored thread 628
21/10/201620:30OptiBiotix - Better Science, Better Health. Better buy some!16,602
18/8/201612:36Optibiotix (OPTI) wins investors as platforms expand9
07/4/201608:23Tasty RNS-

Add a New Thread

Optibiotix H. (OPTI) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
21/10/2016 16:14:0667.005,0003,350.00O
21/10/2016 15:58:0768.002,0001,360.00O
21/10/2016 15:53:3268.506,5004,452.50O
21/10/2016 15:53:0068.025,0003,401.00O
21/10/2016 15:52:0168.025,0003,401.00O
View all Optibiotix H. trades in real-time

Optibiotix H. (OPTI) Top Chat Posts

Optibiotix H. Daily Update: Optibiotix H. is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker OPTI. The last closing price for Optibiotix H. was 68.75p.
Optibiotix H. has a 4 week average price of 68.80p and a 12 week average price of 71.94p.
The 1 year high share price is 101.50p while the 1 year low share price is currently 48.75p.
There are currently 78,150,534 shares in issue and the average daily traded volume is 95,688 shares. The market capitalisation of Optibiotix H. is £53,533,115.79.
parob: Q&A with Stephen O'Hara Chief Executive Officer at Optibiotix Health PLC (LON:OPTI)Optibiotix Health PLC (LON:OPTI) Chief Executive Officer Stephen O'Hara caught up with DirectorsTalk to discuss the new appointment of Martin Hunt as Chairman at SkinBiotics, how this fits into their strategy and what it means for shareholders Q1: Now Stephen, can you tell me more about the appointment of your new Chairman at the SkinBiotix division of Optibiotix Health?A1: Yes, sure. In July of this year Optibiotix announced a strategy to demerge and list as separate divisions and the appointment of the Chairman that we announced in the RNS is the start of this process. It's the process of demerging SkinBiotix and we think this is an important step in the development of SkinBiotics as we build a dedicated team, with dedicated leadership who have the expertise in the biotherapeutic space. I think investors have to realise that it's a very different space to the other Optibiotix divisions and requires specialised industry knowledge in cosmetics, medical devices and in pharmaceuticals and Martin's appointment is to start a process of building a dedicated team and a dedicated leadership with the industry knowledge and expertise to fully exploit the opportunities that we see in the microbiome space particularly in the skin microbiome space. Q2: So what could this mean for Optibiotix's investor and how will it fit into your overall strategy?A2: Well our strategy is to build value for shareholders as part of that process, we're looking to build each division to a point where we can demerge then list it separately, if you look at SkinBiotix and look at the area that it works in, we don't believe that the market really recognises the value within SkinBiotix, let me give you a couple of examples. The first example is the size of the market opportunity in skin so these market opportunities include cosmetic skin care, a market of $121 billion, healthcare-acquired infections, a market of $82 billion, dermatology, and $10 billion on wound care. I guess the other aspect is that if you look at the other ways in terms of value in a company over the market opportunities that it's targeting is the value of comparison so SkinBiotix is in the biotherapeutic space and if you could comparate a company such a 4D Pharma their valuations tend to be in the hundreds of millions rather than the tens of millions and we think that with SkinBiotix the true value of the division within Optibiotix is not being fully realised. By taking it out of Optibiotix and putting it into a separate company, which is demerge Optibiotix and then list it separately will best realise value for shareholders and there's other examples of this that have set a precedent for this type of approach and they include Racal who spun off Vodafone and Chubb and more recently Paypal from Ebay. What it means in terms of shareholders is typically they retain their position in Optibiotix but they also gain a proportional position in the new listed company so from a shareholder point of view it's a way of greatly increasing the value of their shareholding. Q3: With that in mind then, when do you think we can expect any listing to happen?A3: We can't give the exact details of when the listing will happen but this is part of the process of looking to list SkinBiotix separately, timing will be market sensitive and we will announce an RNS on that nearer the time. We look at market conditions over the forthcoming months, we look at putting the team in place and getting the right people who we feel can lead a team and who have the expertise to fully exploit the opportunity, once we have those in place we will produce an RNS, we will signal our intent then in terms of a listing. We see this as not a longer term opportunity, we see this, dependant on market conditions, as a short to medium term opportunity and we're pressing ahead on that as I indicated in the earlier question and the first part of that process was appointing a Chairman. So we're really excited by the opportunity and we think it's a great way to build shareholder value, we think if we get it right and we take it to the market then very much like as we did with OptiBiotix we were able to get a great increase in share price and value over a short period of time. We think that SkinBiotix opportunity is very similar; big markets, big opportunities and as I said earlier comparator companies with high market valuations, I think it's a great opportunity here for investors in Optibiotix Health.
michaelmouse: post 585 - "Anyway let's see what develops, but bargepole territory for me with every extra bit of PR they produce to try and pump up the price." Oh dear!! Same old, same old. Loss making company tries diversionary tactic i.e. "spin-off" story. Share price has lost 40% of it's value in the past year. A desperate PR attempt is made over the weekend to try and pump up the price next week and halt a total collapse. Yawn. I hope it works for holders because that "rolling top" on the chart is a classic. If the share price doesn't rise on Monday (substantially) then 40p here we come. They need a strong share price to get a spin-off IPO away hence the tipsters trying to get the PIs all worked up over the weekend. The facts remain. They are years away from meaningful revenues and profitability. They need shed loads of more cash. Hence the attempt at a "spin-off". Nervous day for holders on Monday. Share price needs to "take off" on strategic pumping campaign. Follow the Nanoco story. Even when deals are struck, the licensing payments are often laughable. "The upfront licence fees associated with the agreements are to be recognised over the period of Nanoco's contractual support. It is expected that GBP0.5 million will be released to revenue in the year ending 31 July 2017 and GBP0.7 million will be released over the following six years ending 31 July 2023."
riskybusiness1: Within a a few years of listing Opti from concept grew by over 1000%.....My idea of the de merger is that Opti will raise maybe £4m and say for example skinbiotix is also worth £4m. The new company is now worth £8million. Taking this as an example opti currently owns 100% of £4m skinbiotix (51% if u take Manchester uni into consideration - call it 100% to save confusion). My idea is that following the listing Opti will then own 50% of a company now worth £8m. Kind of the same concept of reversing in to a shell. We all know how that went with Opti in a very short space of time. Skinbiotix is the division more geared towards the pharma market. As we all know these companies bring ridiculous valuations. All Opti holders at the time will be given a percentage in this new company equivalent to current holdings within Opti - those in around the 8-10p level of Opti should recognise this as another huge opportunity to make a considerate amount of money. Also as Opti will retain say that 50% of the new £8m skinbiotix - as this company grows Opti share price will increase with it.Seeing as Opti bought 51% of the ip for 250,000£, if you take my example above Opti have increased the skin ip immediately from £250,000 into £2m. This is how you start to realise the value. If I was on Opti board I'd be trying to negotiate a further % of skin ip from Manchester.
parob: Some interesting chatter this weekend over on the iii board - thought you guys might be interested. One poster called 'whenimrich com' wrote:"Nice to see the shareprice rise on the back of a cleared stock overhang, as reported by TW on share price He also mentions the impending demerger and how the shares will be re - rated for sure when it is announced to 100p + in maybe a couple of weeks. I understand that holders will get a similar percentage of shares in the new company as they hold in Opti which is understandable, but what I dont understand is what will happen to the share price of Opti after demerger? - if the new company becomes seperated from Opti then the price of Opti should surely fall to allow for this?Thinking of it basically - if you have a company worth 100% and divide it into 5 pieces (for example) then the original company is then worth 20% Can anyone explain how this will work?"In response 'Novy kluk' wrote:"Hi whenimrich com,I will try and answer your question. I think the way such a process would work is the following;# The company will NOT BE GIVING AWAY the shares in the demerged entities, they will be selling them to the market.# Recall SOH's comment in an RNS some months back, that the BOD believes the current value the market puts on the company (e.g. currently equivalent to about 75p per share) is less than the sum of the individual entities, right!# So when the individual entities are floated, the BOD will decide (no doubt with the "help" of exorbitantly paid advisors), at what price they want to "sell the demerged company(s)" to the market.# At this point I am NOT trying to predict what that/those prices might be! I am only using figures now for purposes of explanation!# Also recognise (as I'm sure you do) that the parent company Optibiotix Holdings, is very unlikely to divest more than 49% of the shares in each entity!# So IMHO they are likely to establish a price for each entity - say (FOR EXAMPLE ONLY) 40p per share for Skin Biotix.# Then when they "float", existing shareholders will be allocated "a quantity" of these 40p shares in "some proportion" to their holding. # Parent Optibiotix Holding company will retain 51% of these shares - if the float is successful - valued at 40p per share - thus significantly increasing the value of the company!# And the remaining shares will be sold to the market in an "open offer".# If for "Skin Biotix" this is done on NASDAQ as well as AIM, then there could well be a "feeding-frenzy" for these shares, and the price could well increase significantly - this would further increase the value of the Parent Holding company (who hold 51%). And of course increase the values of each existing shareholders holding.# Continuing this process, if say 5 entities were demeged (of course they might be at varying prices depending on their perceived potentials), and assuming the "floats" were managed properly and were successful, then the Parent company, "Optibiotix Holdings" will hold 51% in each of the entities - then most likely to at prices which additively will be significantly higher than today's 75p!Whilst not an expert, I'm sure what I've outlined is quite close to the process that would happen. I hope this helps!GLTA NKI should have added that the proceeds of the sale of shares in the "open offer", will also of course accrue to the Parent "Optibiotox Holdings"!NK"
lodger: Say OPTI create a new company and give holders shares in proportion to their current holding, would SB companies automatically give you new bets with the equivalent number of shares, or would they say you don't actually hold the shares so you don't have the rights so if the OPTI share price halves then tough (even though actual holders might not be any worse off because they hold new company shares to roughly balance the drop). It depends on whether the SB companies treat the shares they've had to buy to offset your bet, but I've no idea about rights etc...
riskybusiness1: 2016 has performed better than planned I would say other than share price performance... Thought we'd be looking at 2017 to see products on the shelves. Though the share price has remained stagnate (not helped with consistent seller around 80+ mark which has halted any upward momentum) the progress has been immense in terms of positioning for the future. You could have gone elsewhere made a quick buck however when this lifts off big money will be made. I don't think people realise our value is based upon our ip, we are selling TECHNOLOGY rather than actual products. This ip is then translated in to gaining a minuscule % of these massive markets that are growing at more than 10% per year. Opti has been snapping up ip this year with some being independently valued at £250m - purchased for 250k. Think that actually made the share price go down if I remember?? Reinforces soh reasons for splitting the company up into separate divisions and listing them separately. Many here just looking at the share price rather than what's being created.Obviously we all make money when share price goes up... disappointing little progress on that front this year however I couldn't be happier with the developments. Impatience to go elsewhere will be very costly for many in the long run is my honest opinion. These deals have come out of the blue so far. So many fronts to hear from
elrico: Are GlaxoSmithKline plc, Tissue Regenix Group plc and Optibiotix Health plc must-have health stocks? Optibiotix Health(LSE: OPTI) is behind Tissue Regenix on the road to commercialisation, but like the regenerative tissue company, it has genuine and valuable intellectual property. In Optibiotix's case, this is centred on tackling obesity, high cholesterol and diabetes with patented compounds that change the way microbes in the body work and interact. Optibiotix may have no commercial revenues at this stage, but a number of joint development, cost-sharing and option agreements are in place, including with Slimfast and an unnamed "multinational consumer goods company". At a current share price of 80p, Optibiotix is valued at £62m. At this stage of its development, Optibiotix remains a speculative investment for those with a high tolerance for risk, but big business is clearly interested in the company's technology and the potential markets are huge. These markets were further extend just last week when Optibiotix filed a new patent for microbial proteins with the potential to tackle hospital superbugs such as MRSA. Optibiotix is a young company at a relatively early stage of development, but the growth prospects for even some established profit-making small caps can be missed on occasions, because this area of the market is under-researched by professional analysts.
elrico: The Sovereign Society valuation had me thinking how they came by this valuation target of £7.40p? OK, no time-frame had been set for this. Typically, brokers tend to look 18/24 months ahead, so this did not seem too far in the distance to wait for such a healthy return. Now I do not claim to be a whiz with numbers, I'm more akin to seeking out a speculative punts on what I think is going to be a hot sector in a similar time-frame brokers. So, do your own crunching because I may well get this wrong, so please feel free to wag a finger at me and assist me in getting more realistic numbers. Thanks in advance. :-) PE ratios in the biotech sector can be varied as they can be meaty, so it can be easy to get carried away with your PE forecasts, especially when we are in the situation we are with OPTI. If you look at the biotech breakdown, you'll find a lot of companies don't have a PE because many are young biotech companies that have yet to make a profit, which is where we are now with OPTI. If we look at a company I would hope we are all familiar with, Shire PLC, it has a PE of 18.24 (26.21 ADVFN) which is may seem pretty high but it's not. SHP, Market Cap of £23.758B with pre tax profits of c£160m. I am not comparing OPTI with Shire, clearly, we can't at this stage for a number of reasons. Perhaps we are better off comparing 4D. Like OPTI, it has no PE, 4D has cnet debt of £3m, yet has a market cap of £560m and at least 3 years away from commercial production and will be in R&D mode for years and the pharma route just drains cash and quickly. Both OPTI and 4D have similar amount of shares floating around. SOH likes comparing OPTI with 4D, so who am I to go against him. I don't think I am too optimistic in estimating OPTI have a PE of 25. The reasoning behind this because this brings us pretty close to the SC valuation of £7.40. I have used a profit figure of £20 mil, being the figure quoted here a number of times as being a reasonable guestimate given the sectors OPTI have in their sights, and of course the MN nature of at least 3 companies OPTI have JV with. Now I have that out of the way. Pre tax profit £20 m PE 25 Share price £6.80 Or ultra conservative Pre tax profit £10 m PE 12.5 Share price £3.40 However, if we use ADVFN's PE ratio of 47.8 this put's OPTI nearer £13 with profits of £20m. That said, I don't think ADVFN's PE data is correct. I believe I have been conservative with my PE forecasts, because OPTI are in several very hot sectors within the health care sectors, which will excite the market once products are on the shelves.
talkingtrades: Courtesy of ipedro from iii. Interesting read and I tend to agree:"Anyone spot the deliberate mistake by their own broker, Hybridan?No wonder they forecast such puny unrisked share price valuations by category:OptiBiotix sum of the parts valuation.... Drivel - this is a current market valuation - Anyone and his cat knows a company's share price or market cap valuation will reach MANY times EACH current market sector valuation. They have no correlation to any share price forecast at all - you can't do it! It's guesswork. That's why you have a P/E based formula per sector - and even that's a finger-in-the-air valuation.Cholesterol 58.8m (Benecol) Risk weighting '40%' - Drivel.SweetBiotix 27.5m (Stevia) Risk weighting '75%' - Drivel.Weight Management (HerbalLife) 20.7m Risk weighting '55%' - Drivel.Platform (Nestle) 43.3m Risk weighting '35%' - Drivel.Health Care Acquired Infections 19.4m Risk weighting '95%' - Drivel.Eczema (Eczema therapeutic market) 23.8m Risk weighting '95%' - Drivel.Psoriasis (Psoriasis therapeutic Market) 41.3m Risk weighting '95%' - Drivel.Wound Care (Anti-infective dressings) 46.9m Risk weighting '95%' - Drivel.Cosmetic skin care (Botox) 13.8m Risk weighting '95%' - Drivel.Pre diabetic supplement (Diabetic-centric supplements) 6.3m Risk weighting '95%' - Drivel.Cash 3.4m Estimated 2016 year end - would be nice.Indicative Valuation 90.6p - DrivelDiluted shares in issue 85.5 - CORRECT!Indicative valuation per share (p) 106.0 - DrivelThey've done this on purpose so they can massage their own egoes while they follow the share price all the way up. On market realisation and further commercialistion and MN partner deals, OPTI could be multiples of this forecast before they sign their first sales order.Also, nice misprint on the broker note 'These products are therefore an asset in terms of OptiBiotix's own product development but importantly can also be marketed as a product enhancer to any producer of probiotics, a market expected to be worth $46.5m by 2020 according to Markets and Markets.'What's the Probiotic market expected to be worth in 2020 again? Just the three noughts missing on that one...'Millions' is not what I'm here for... wonder TW says Hybridan should be strung up with piano wire."
elrico: I am not sure what some people expected today, but some are being short-sighted and impatient, almost like day traders. Personally, as selfish as it may seem, I am quite happy for the shares to remain where they are, because there are a small number of options left in my small portfolio that could yield me good returns in the short term, further allowing me to buy a few more OPTI, as foolhardy as this may seem, in what is already a massively overweight position, you have to take these calculated risks and the Hybridan report allows us all a glimpse of the future of each sector of OPTI’s IP, because it breaks down the risk for us, thus allows us an educated guess at the potential price as each IP is de-risked, we still need hard cash to further extrapolate EPS, possibly a further boost to the share price. For example, the new price target is 109p on a de-risked weighted percentage, cholesterol being the lowest risk weight so far, at 40% = to 35.3p per share, implying a 23.5p upside, or 58.8p, so an optimist might argue as each IP is de-risked, the share price should be somewhere near 301.8p. I am not suggesting this is where we are now, but I do expect significant progress this year that will have us north of where we are now. Clearly, as we de-risk each market, be it cholesterol, weight management, or sugars, the share price will look after itself, and as clarity on the real revenues generated by royalties, the share price will ping like a golf ball off a well timed drive. It’s clear OPTI’s science is attracting a wider market, not just a European market, but a global market, this is demonstrated with the US MN currently being completed, 2 Dutch companies, both of which are MN, Italy and Spain also have companies involved, all of which have a global footprint. The unsophisticated investor will just look at the increased cashburn (as modest as it is) and draw the wrong conclusion, the cash balance of £4.3 mil and compare this with the market cap, and draw the wrong conclusion, etc, because they don’t know how to value companies, and these people will never chose the right company, or make money without LUCK and TIMING on their side. Some people are just unable to see the wood for the trees. These people don’t understand the management caliber, the IP, the marketability of each of the area’s OPTI have at their begging. These people don’t appreciate the time it takes to negotiate with MN, the procedures involved and probably don’t have the patience and certainly don’t have the vision to look further than their own nose. There's much to say about OPTI just for what it has achieved in 2016, I haven’t even touched on UoM collaboration and what this means for the future and potential patents and IP, I guess we will have to wait to drool over this later in the year. The company has 6 commercial JV in play, right now, all of which are for 6 figures sums, none of which are in today's accounts because of the timing, of course. I expect each of these 6 JV to yield collaborative royalties dwarfing the initial ante each company has placed to be at the table; each has the potential to yield multiple products, with further potential for crossover products, be it weight management, animal feed-stock, cholesterol or hypertension, be it new products or additives to existing products, probably both, because the IP seems to be so versatile across all platforms. A tad hastily written because time is not on my side today.
Optibiotix H. share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20161022 01:50:39